Literature DB >> 24500966

The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis.

Darragh Duffy1, Rasha Mamdouh, Melissa Laird, Charlotte Soneson, Lenaig Le Fouler, Maï El-Daly, Armanda Casrouge, Jérémie Decalf, Amal Abbas, Noha Sharaf Eldin, Magnus Fontes, Mohamed Abdel-Hamid, Mostafa K Mohamed, Mona Rafik, Arnaud Fontanet, Matthew L Albert.   

Abstract

UNLABELLED: Viral hepatitis is the leading cause of liver disease worldwide and can be caused by several agents, including hepatitis A (HAV), B (HBV), and C (HCV) virus. We employed multiplexed protein immune assays to identify biomarker signatures of viral hepatitis in order to define unique and common responses for three different acute viral infections of the liver. We performed multianalyte profiling, measuring the concentrations of 182 serum proteins obtained from acute HAV- (18), HBV- (18), and HCV-infected (28) individuals, recruited as part of a hospital-based surveillance program in Cairo, Egypt. Virus-specific biomarker signatures were identified and validation was performed using a unique patient population. A core signature of 46 plasma proteins was commonly modulated in all three infections, as compared to healthy controls. Principle component analysis (PCA) revealed a host response based upon 34 proteins, which could distinguish HCV patients from HAV- and HBV-infected individuals or healthy controls. When HAV and HBV groups were compared directly, 34 differentially expressed serum proteins allowed the separation of these two patient groups. A validation study was performed on an additional 111 patients, confirming the relevance of our initial findings, and defining the 17 analytes that reproducibly segregated the patient populations.
CONCLUSIONS: This combined discovery and biomarker validation approach revealed a previously unrecognized virus-specific induction of host proteins. The identification of hepatitis virus specific signatures provides a foundation for functional studies and the identification of potential correlates of viral clearance.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24500966     DOI: 10.1002/hep.26901

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

Review 1.  Immune responses and immunopathology in acute and chronic viral hepatitis.

Authors:  Eui-Cheol Shin; Pil Soo Sung; Su-Hyung Park
Journal:  Nat Rev Immunol       Date:  2016-07-04       Impact factor: 53.106

2.  Development of a Bead-Based Multiplex Assay for the Analysis of the Serological Response against the Six Pathogens HAV, HBV, HCV, CMV, T. gondii, and H. pylori.

Authors:  Angela Filomena; Frank Pessler; Manas K Akmatov; Gérard Krause; Darragh Duffy; Barbara Gärtner; Markus Gerhard; Matthew L Albert; Thomas O Joos; Nicole Schneiderhan-Marra
Journal:  High Throughput       Date:  2017-10-30

3.  CXCL10 is produced in hepatitis A virus-infected cells in an IRF3-dependent but IFN-independent manner.

Authors:  Pil Soo Sung; Seon-Hui Hong; Jeewon Lee; Su-Hyung Park; Seung Kew Yoon; Woo Jin Chung; Eui-Cheol Shin
Journal:  Sci Rep       Date:  2017-07-25       Impact factor: 4.379

4.  Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C.

Authors:  Geórgia Nascimento Saraiva; Natalia Fonseca do Rosário; Thalia Medeiros; Paulo Emílio Côrrea Leite; Gilmar de Souza Lacerda; Thaís Guaraná de Andrade; Elzinandes Leal de Azeredo; Petronela Ancuta; Jorge Reis Almeida; Analúcia Rampazzo Xavier; Andrea Alice Silva
Journal:  Mediators Inflamm       Date:  2018-05-27       Impact factor: 4.711

5.  Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma.

Authors:  Jacqueline Estevez; Vincent L Chen; Ondrej Podlaha; Biao Li; An Le; Philip Vutien; Ellen T Chang; Yael Rosenberg-Hasson; Zhaoshi Jiang; Stefan Pflanz; Dongliang Ge; Anuj Gaggar; Mindie H Nguyen
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

6.  Integrative genetic and immune cell analysis of plasma proteins in healthy donors identifies novel associations involving primary immune deficiency genes.

Authors:  Lluis Quintana-Murci; Darragh Duffy; Antonio Rausell; Barthelemy Caron; Etienne Patin; Maxime Rotival; Bruno Charbit; Matthew L Albert
Journal:  Genome Med       Date:  2022-03-09       Impact factor: 11.117

7.  Comparative Analysis of Liver Injury-Associated Cytokines in Acute Hepatitis A and B.

Authors:  So Youn Shin; Sook-Hyang Jeong; Pil Soo Sung; Jino Lee; Hyung Joon Kim; Hyun Woong Lee; Eui-Cheol Shin
Journal:  Yonsei Med J       Date:  2016-05       Impact factor: 2.759

8.  Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post-translational modification: prospective placebo-controlled clinical studies.

Authors:  Jérémie Decalf; Kristin V Tarbell; Armanda Casrouge; Jeffrey D Price; Grace Linder; Estelle Mottez; Philippe Sultanik; Vincent Mallet; Stanislas Pol; Darragh Duffy; Matthew L Albert
Journal:  EMBO Mol Med       Date:  2016-06-01       Impact factor: 12.137

9.  Protein biomarkers discriminate Leishmania major-infected and non-infected individuals in areas endemic for cutaneous leishmaniasis.

Authors:  Wafa Kammoun-Rebai; Ikbel Naouar; Valentina Libri; Matthew Albert; Hechmi Louzir; Amel Meddeb-Garnaoui; Darragh Duffy
Journal:  BMC Infect Dis       Date:  2016-03-24       Impact factor: 3.090

10.  Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients.

Authors:  Cécile Alanio; Francesco Nicoli; Philippe Sultanik; Tobias Flecken; Brieuc Perot; Darragh Duffy; Elisabetta Bianchi; Annick Lim; Emmanuel Clave; Marit M van Buuren; Aurélie Schnuriger; Kerstin Johnsson; Jeremy Boussier; Antoine Garbarg-Chenon; Laurence Bousquet; Estelle Mottez; Ton N Schumacher; Antoine Toubert; Victor Appay; Farhad Heshmati; Robert Thimme; Stanislas Pol; Vincent Mallet; Matthew L Albert
Journal:  Elife       Date:  2015-11-14       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.